FLEBOGAMMA 5% DIF Human normal immunoglobulin 20g/400mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 20g/400ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 10g/200mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 10g/200ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; sorbitol; water for injections - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 5g/100mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 5g/100ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 2.5g/50mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 2.5g/50ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; sorbitol; water for injections - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

FLEBOGAMMA 5% DIF Human normal immunoglobulin 0.5g/10mL intravenous use injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

flebogamma 5% dif human normal immunoglobulin 0.5g/10ml intravenous use injection vial

grifols australia pty ltd - normal immunoglobulin, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: human immunoglobulin a; water for injections; sorbitol - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, wiskott aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenia purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, guillian barre syndrome. allogenic bone marrow transplantation.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 10 mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml pre-filled syringe

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 5 mL pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml pre-filled syringe

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 5 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 5 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 1 g - injection, solution - excipient ingredients: water for injections; proline; polysorbate 80 - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 10 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 10 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 2 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.

HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 50 mL vial Australia - English - Department of Health (Therapeutic Goods Administration)

hizentra human normal immunoglobulin 20% solution for subcutaneous injection 50 ml vial

csl behring australia pty ltd - normal immunoglobulin, quantity: 10 g - injection, solution - excipient ingredients: polysorbate 80; proline; water for injections - replacement therapy in adults and children in: - primary immunodeficiency disease (pid) and - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulatory therapy in: - chronic inflammatory demyelinating polyneuropathy (cidp) as maintenance therapy after stabilisation with ivig.